Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
Recent Content
- Oral treatment for ovarian cancer put on FDA fast track
- J&J seeks approval in EU of Tecvayli-Darzalex for hard-to-treat myeloma
- 1st 4 patients in AML treatment combo trial show response
- A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
- The efficacy and safety of CAR-T therapy in relapsed or refractory multiple myeloma patients: a systematic review and meta-analysis
- (no title)
- (no title)
- (no title)
- (no title)
- (no title)